Yahoo Finance

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of ...
Nasdaq

Serina Therapeutics Secures Additional $5 Million Financing to Advance SER-252 into Phase 1 Trial for Advanced Parkinson's Disease

Serina Therapeutics secured a second $5 million funding tranche for advancing SER-252 into a Phase 1 trial in Parkinson's disease. Serina Therapeutics, Inc. has successfully closed the second $5 ...
manilatimes

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 - HUNTSVILLE, AL, Feb. 24, 2026 (GLOBE NEWSWIRE ...